TABLE II.

Spearman correlations of skin biomarkers with AD clinical severity based on SCORAD, r > 0.4/<20.4, and P < .05

SCORAD
Lesional skin									Nonlesional skin
Infants			Children			Adolescents			Infants			Children			Adolescents
Marker	r	P value	Marker	r	P value	Marker	r	P value	Marker	r	P value	Marker	r	P value	Marker	r	P value
IL-21	0.574	.016	CCL21	0.842	.004	CAMP	0.697	.007	IL-26	0.493	.044	IL-9	0.870	.002	CXCL1	0.925	<.001
IL-34	20.575	.016	IL1B	0.830	.006	K16	0.574	.035	IL-1RL1	0.485	.049	IL-19	0.850	.006	S100A12	0.859	<.001
PPL	20.569	.017	IL31	0.827	.003	IL-23A	0.560	.040	IL-37	20.483	.049	DEFB4B	0.800	.014	DEFB4B	0.842	<.001
LCN2	20.510	.036	IFNG	0.77	.014	S100A8	0.552	.044				IL-17F	0.749	.020	IL-1B	0.789	.001
CCL22	20.499	.041	MMP12	0.745	.018	IL-4R	0.538	.050				PPL	0.700	.043	S100A8	0.771	.002
			IL-22	0.733	.021	FLG	20.622	.020				CLDN8	20.883	.003	CXCL11	0.758	.003
			CXCL1	0.721	.024							CLDN1	20.833	.008	S100A9	0.754	.003
			IL-4R	0.721	.024							IL33	20.783	.017	CCL17	0.754	.003
			IL-15	0.709	.028							IL34	20.717	.037	KRT16	0.749	.003
			CXCL11	0.697	.031										IL-20	0.745	.003
			OX40	0.697	.031										CAMP	0.723	.005
			IL-10	0.697	.031										CCL19	0.719	.005
			IL-17A	0.693	.026										IL-10	0.697	.007
			CCL18	0.685	.035										IL-22	0.697	.007
			CCL13	0.685	.035										IL-23A	0.692	.008
			CCL7	0.673	.039										CXCL9	0.675	.010
			IL-13	0.661	.044										CCL7	0.666	.011
			FOXP3	0.648	.049										PI3	0.657	.013
			CLDN1	20.709	.028										IL-19	0.648	.015
															CCL20	0.644	.015
															LCN2	0.644	.015
															CXCL8	0.640	.016
															MMP12	0.635	.017
															IFNG	0.631	.018
															CCL13	0.626	.019
															CXCL10	0.626	.019
															KYNU	0.607	.021
															IL31	0.603	.022
															S100A7	0.596	.028
															IL-13	0.591	.029
															CCL18	0.569	.037
															CCL22	0.565	.038